In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

Angiotensin II type 1 and 2 receptors (AT 1 and AT 2) are implicated in the pathogenesis of MFS. Researchers have tested the efficacy of the angiotensin-converting-enzyme (ACE) inhibitor ...

and the action of the angiotensin II molecule, once synthesized, can be blocked at the receptor. In practice, only ACE inhibitors and ARBs have provided safe and effective management of ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

But while the benefits of GLP-1 receptor agonists for the treatment of type 2 diabetes, obesity and cardiovascular disease are well known, their impact on chronic kidney disease (CKD) has been less ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...